Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CA12-targeted radioimmunotherapy is an investigational targeted radionuclide therapy (radioimmunotherapy) approach designed for the treatment of solid tumors, particularly glioblastoma. The therapy targets carbonic anhydrase XII (CA12 or CA XII), a transmembrane enzyme overexpressed in hypoxic and acidic tumor microenvironments but largely absent in healthy brain tissue. The primary clinical candidate representing this platform is ITM-31 (formerly LuCaFab), which consists of a CA12-specific monoclonal antibody Fab fragment (6A10-Fab) conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Administered directly into the post-surgical resection cavity (intracavitary), the therapy bypasses the blood-brain barrier to deliver localized, cytotoxic beta radiation directly to residual glioblastoma cells, aiming to eliminate micro-metastases and prevent tumor recurrence while sparing surrounding healthy brain tissue.
| Indication | Highest phase | Status |
|---|---|---|
| glioblastoma, IDH-wildtype | In development | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: glioblastoma, IDH-wildtype
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CA12-targeted radioimmunotherapy.
Work on CA12-targeted radioimmunotherapy? Claim this page to correct or add information. Claim this page